Quadruple induction therapy including antithymocyte globulin or interleukin-2 receptor antibody or FK 506-based induction therapy after liver transplantation

Transplantation Proceedings

Volumn 31, Issue 1-2, 1999, Pages 380-

  Lohmann, R ^a   Langrehr, J M ^a   Klupp, J ^a   Neumann, U ^a   Guckelberger, O ^a   Muller A R ^a   Nussler N C ^a   Jonas, S ^a   Lang, M ^a   Settmacher, U ^a   Bechstein, W O ^a   Neuhaus, P J ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; INOLIMOMAB; INTERLEUKIN 2 RECEPTOR ANTIBODY; PREDNISOLONE; TACROLIMUS; THYMOCYTE ANTIBODY;

CLINICAL PROTOCOL; CONFERENCE PAPER; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; FOLLOW UP; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTIOUS COMPLICATION; LIVER TRANSPLANTATION; LONG TERM CARE; MAJOR CLINICAL STUDY; PNEUMONIA; PRIORITY JOURNAL; SEPSIS;

EID: 0345130083     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0041-1345(98)01670-4     Document Type: Conference Paper

References (3)

1. Neuhaus P., Bechstein W.O., Blumhardt G., et al. Transplantation. 55:1993;1320.
2. Langrehr J.M., Nüssler N.C., Neumann U., et al. Transplantation. 63:1997;1772.
3. Neuhaus P., Blumhardt G., Bechstein W.O., et al. Transplantation. 59:1995;31.